Digital Breast Tomosynthesis Screening In women presenting with signs or symptoms, including a palpable breast mass, screening DBT, with or without DM, is not useful as the initial imaging study. Screening mammography is provided to women without signs or symptoms of breast disease. FDG-PET Breast Dedicated There is no relevant literature to support the use of fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET breast dedicated in the initial evaluation of a woman presenting with a palpable mass [2]. In several series evaluating palpable breast abnormalities [18-20], the sensitivity of mammography alone was 86% to 91%. Mammography likely does not need to be repeated if it was performed within the past 6 months [21]. This Palpable Breast Masses modality may be particularly useful in women with almost entirely fatty breasts, in which mammography alone was shown to have a high sensitivity (96%) and specificity (93%) in the evaluation of palpable breast masses [22]. Mammography Screening In women presenting with signs or symptoms, including a palpable breast mass, screening mammography is not useful as the initial imaging study. Screening mammography is provided to women without signs or symptoms of breast disease. MRI Breast There is no relevant literature to support the use of MRI breast with or without intravenous (IV) contrast in the initial evaluation of a woman presenting with a palpable mass [2,23-25]. Sestamibi MBI There is no relevant literature to support the use of Tc-99m sestamibi molecular breast imaging (MBI) in the initial evaluation of a woman presenting with a palpable mass. US Breast US may be considered as an initial means of imaging if the patient has had a recent negative mammogram within the past 6 months. In a study of women presenting with a palpable breast mass with a negative mammogram within the previous 6 to 12 months, US detected a finding in 50.3% of 311 cases, whereas repeat mammography detected a change in 12.9% of cases [21].
Palpable Breast Masses. Digital Breast Tomosynthesis Screening In women presenting with signs or symptoms, including a palpable breast mass, screening DBT, with or without DM, is not useful as the initial imaging study. Screening mammography is provided to women without signs or symptoms of breast disease. FDG-PET Breast Dedicated There is no relevant literature to support the use of fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET breast dedicated in the initial evaluation of a woman presenting with a palpable mass [2]. In several series evaluating palpable breast abnormalities [18-20], the sensitivity of mammography alone was 86% to 91%. Mammography likely does not need to be repeated if it was performed within the past 6 months [21]. This Palpable Breast Masses modality may be particularly useful in women with almost entirely fatty breasts, in which mammography alone was shown to have a high sensitivity (96%) and specificity (93%) in the evaluation of palpable breast masses [22]. Mammography Screening In women presenting with signs or symptoms, including a palpable breast mass, screening mammography is not useful as the initial imaging study. Screening mammography is provided to women without signs or symptoms of breast disease. MRI Breast There is no relevant literature to support the use of MRI breast with or without intravenous (IV) contrast in the initial evaluation of a woman presenting with a palpable mass [2,23-25]. Sestamibi MBI There is no relevant literature to support the use of Tc-99m sestamibi molecular breast imaging (MBI) in the initial evaluation of a woman presenting with a palpable mass. US Breast US may be considered as an initial means of imaging if the patient has had a recent negative mammogram within the past 6 months. In a study of women presenting with a palpable breast mass with a negative mammogram within the previous 6 to 12 months, US detected a finding in 50.3% of 311 cases, whereas repeat mammography detected a change in 12.9% of cases [21].